CTOs on the Move

ArcherDX

www.archerdx.com

 
ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.archerdx.com
  • 2477 55th Street Suite 202
    Boulder, CO USA 80301
  • Phone: 303.357.9001

Executives

Name Title Contact Details

Funding

ArcherDX raised $35M on 03/20/2018
ArcherDX raised $60M on 05/15/2019
ArcherDX raised $55M on 12/17/2019

Similar Companies

The Hamner Institutes for Health Sciences

The Hamner Institutes for Health Sciences is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quellis Biosciences

Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases – and underserved by current treatment options. The Company is based in Boston, and is led by partners from the biotech incubator Viridian LLC in collaboration with team at biotech accelerator Xontogeny LLC, and with funding from the Perceptive Xontogeny Venture Fund. The Quellis team has deep experience in mAb discovery and development, company creation, and private and public biotech investment. Our shared goal is to create meaningful medicines for every disease we target.

Dermavant

A Passion for Science and a Commitment to Dermatology Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. We are dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients` lives. The patient is at the heart of everything we do.

454 Life Sciences, a Roche company

454 Life Sciences' system enables one individual to prepare and sequence an entire genome after performing a single sample preparation, irrespective of the size of the genome being studied. The hallmark of 454 Life Sciences' technology is the

Absci

Absci is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. We built our Integrated Drug Creation™ Platform to accelerate discovery of novel biotherapeutic drug candidates and generation of the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to develop new protein-based drugs, including those that may be impossible to make with other technologies. Our goal is to enable the creation of better medicines by Translating Ideas into Drugs.